Heptapeptide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-02-13. Anything still debated is marked as such rather than presented as settled.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Reported observations after unregulated use include shifts in skin pigmentation and, in some accounts, unintended changes to moles and other lesions. Whether these outcomes are causally linked to the compound, and how often they occur, remain open questions because controlled data are scarce. The absence of standardised dosing and verified product purity complicates interpretation. Researchers have called for better surveillance and analytical characterisation of samples obtained outside regulated channels. Conclusions drawn from anecdotal evidence should be treated as provisional.
Melanotan-2 has not received marketing authorisation from major regulatory agencies for any therapeutic indication. Several jurisdictions classify it as a prescription-only medicine or a controlled substance when supplied for human use. Because approved products do not exist, material sold online usually sits outside pharmaceutical supply chains and formal quality oversight. Regulators have issued public notices describing the compound as unapproved. Enforcement varies, and the legal position differs between countries, which complicates any single general statement about its status.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Unapproved for therapeutic use | No marketing authorisation from major agencies |
| Legal classification | Varies by jurisdiction | Prescription-only or controlled in several countries |
| Common synonyms | Melanotan II; MT-II | Also referenced by catalogue codes |
| Typical analytical method | Reverse-phase HPLC | Often paired with mass spectrometry |
| Primary literature focus | Receptor pharmacology | Pigmentation and melanocortin signalling |
Quality assessment of research-grade peptide rests mainly on reversed-phase high-performance liquid chromatography for purity and on mass spectrometry for identity confirmation. A single main peak above a stated threshold, commonly ninety-eight percent by peak area, is the usual release criterion applied by suppliers. Independent analyses commissioned by laboratories and consumer organisations have repeatedly reported discrepancies between label claims and measured content, including truncated sequences, residual trifluoroacetate, and lower-than-declared peptide mass. Those findings do not establish that every supplier is unreliable, but they indicate that purity figures printed on a vial are claims requiring verification rather than settled facts.
Regulatory treatment varies by jurisdiction and has changed over time. In several countries the peptide is handled as an unapproved prescription medicine, and import or sale for human use is restricted, while elsewhere it falls under poisons or controlled-substance schedules. Enforcement activity against online vendors has been reported in Australia, New Zealand, the United Kingdom and the United States. Scholarly writing discusses melanotan-2 chiefly as an experimental tool and as a case study in unregulated peptide supply, and its precise legal position in any given country should be checked against current national schedules.
Lyophilised melanotan-2 is comparatively robust when kept dry, cold and dark, and a desiccated powder stored at minus twenty degrees Celsius or below is generally expected to retain its chemical integrity for extended periods. In solution the peptide is far less stable, with degradation proceeding through oxidation of tryptophan and histidine residues, hydrolysis adjacent to the lactam bridge, and aggregation at higher concentrations. Repeated freeze-thaw cycling accelerates loss of the parent peak. Working aliquots are therefore prepared once, held cold, and used without letting the stock return to ambient temperature.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Lyophilized peptide powder is generally stored frozen, protected from light and moisture. Tryptophan residues are susceptible to oxidation, and the lactam bridge can hydrolyze under strongly acidic or basic conditions. Solutions prepared for laboratory work degrade faster than dry powder, and repeated freeze-thaw cycles accelerate loss. Common practice is to aliquot solutions before freezing and to avoid alkaline buffers. Reported stability windows vary with concentration, buffer, and temperature, so exact shelf lives are method-specific rather than universal.
Regulatory status differs by country, and in many places supplying the compound for human consumption is unlawful. Vendors frequently label material as intended for research use only, a designation that shifts stated purpose but does not create a legal pathway for personal use. Certificates of analysis accompanying such products vary widely in detail and provenance. Third-party testing exists but is voluntary, and results are rarely linked to a specific lot in a publicly verifiable way.
Identity testing for a synthetic peptide relies on several complementary methods. Reversed-phase high-performance liquid chromatography separates the target from related impurities and reports purity as a percentage of total peak area. Mass spectrometry confirms molecular mass and can reveal deletions or truncations. Amino acid analysis and peptide mapping provide sequence-level confirmation, while counter-ion content and residual solvents are measured separately. A purity figure alone does not establish identity, so a complete dataset combines chromatographic and spectrometric evidence.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
== History == A high yield and efficient synthesis of 2,6-DCBQ was first provided in 1886 by the chemist Kollrep A. during a systematic investigation into derivatives of phenols. Kollrepp utilized p-nitrophenol as a starting material, converting it into mono- and dichlornated benzoquinones making vibrant yellow cristalline structure. Researchers in 1932 found an optical method for studying reversible organic oxidation-reduction systems, by using hydroquinones to determine equilibrium constants. In 1956 Wessels and van der Veen explored how chlorinated quinones could shuttle electrons. By researching the action of benzoquinones on the Hill reaction. It became a standard tool for isolating the activity of Photosystem II, because of its specific redox potential. Qin et al. detected and quantified 2,6-DCBQ from Canadian municipal drinking water samples. By using highly sensitive liquid chromatography mass spectrometry, 2,6-DCBQ was identified as a major DBP formed during chlorination of raw water containing phenolic contaminants. Since this discovery, research about 2,6-DCBQ has shifted towards its role in human health.
Kennedy Memorial Stadium, which would potentially allow the Commanders to move there in 2027, saying that the bill was "not in the best interest of the American taxpayer". After this bill passed Congress in December 2024, Moore and Washington Commanders owner Josh Harris signed a memorandum of understanding that the team would be responsible for developing the Northwest Stadium site if it moves to RFK Stadium. On April 28, 2025, Harris announced that the team would be building a New Stadium at RFK Campus to open in 2030. In May 2024, Moore signed into law a bill that would transfer ownership of the Pimlico Race Course to the Maryland Thoroughbred Racetrack Operating Authority, allowing for a state-funded, multi-million dollar renovation project of the race course's track to begin and for the construction of a new training center at a separate location. The bill would also consolidate thoroughbred racing in Maryland to Pimlico and have the Maryland state government assume responsibility over racing operations at the course by next year. In June 2026, the State of Maryland acquired the intellectual property rights of the Preakness Stakes after matching an $85 million offer made by Churchill Downs Incorporated.
The UPMC Rooney Sports Complex is a multipurpose, multisport training, sports science, and sports medical complex located along the shore of the Monongahela River in Pittsburgh and is unique in that it combines training facilities for the University of Pittsburgh football team and the Pittsburgh Steelers NFL team in one location with an academically based sports science and medicine program. The complex consists of four centers which include the Center for Sports Medicine, Sports Training Center, Indoor Training Center, and the Fitness and Conditioning Center.
Sources: en.wikipedia.org
residents determined to be at the greatest risk of exposure to counterfeit products through personal prescription drug importation, are aged greater than 45 years, reside in the south or west regions of the U.S., are of Hispanic ethnicity, college educated, poor or near poor poverty status, lacking U.S. citizenship, traveling to developing countries, lacking health insurance, managing high family out-of-pocket medical costs, having trouble finding a healthcare provider, self-reporting fair or poor health status, filling a prescription on the Internet, and using online chat groups to learn about health. Recent evidence suggests that provision of health insurance coverage may effectively reduce importation and the subsequent risk of exposure to counterfeit medicines, especially among particular subpopulations.
Ba(Cl2C=C(Cl)COO)2 → BaCl2 + ClC≡CCl + 2CO2 Dichloroacetylene was discovered as an intermediate in the synthesis of diphenylacetylene with calcium carbide, chlorine and benzene in 1918. It was first synthesized from trichloroethylene by Erwin Ott, W. Ottemeyer and K. Packendorff in 1930.
Bacterial infections may be treated with antibiotics, which are classified as bacteriocidal if they kill bacteria or bacteriostatic if they just prevent bacterial growth. There are many types of antibiotics, and each class inhibits a process that is different in the pathogen from that found in the host. An example of how antibiotics produce selective toxicity are chloramphenicol and puromycin, which inhibit the bacterial ribosome, but not the structurally different eukaryotic ribosome. Antibiotics are used both in treating human disease and in intensive farming to promote animal growth, where they may be contributing to the rapid development of antibiotic resistance in bacterial populations. Infections can be prevented by antiseptic measures such as sterilising the skin prior to piercing it with the needle of a syringe, and by proper care of indwelling catheters. Surgical and dental instruments are also sterilised to prevent contamination by bacteria. Disinfectants such as bleach are used to kill bacteria or other pathogens on surfaces to prevent contamination and further reduce the risk of infection.
Comparatively simple devices are often used to apply counterions of increasing gradient to a chromatography column. Counterions such as copper (II) are chosen most often for effectively separating peptides and amino acids through complex formation. A simple device can be used to create a salt gradient. Elution buffer is consistently being drawn from the chamber into the mixing chamber, thereby altering its buffer concentration. Generally, the buffer placed into the chamber is usually of high initial concentration, whereas the buffer placed into the stirred chamber is usually of low concentration. As the high concentration buffer from the left chamber is mixed and drawn into the column, the buffer concentration of the stirred column gradually increase. Altering the shapes of the stirred chamber, as well as of the limit buffer, allows for the production of concave, linear, or convex gradients of counterion. A multitude of different mediums are used for the stationary phase. Among the most common immobilized charged groups used are trimethylaminoethyl (TAM), triethylaminoethyl (TEAE), diethyl-2-hydroxypropylaminoethyl (QAE), aminoethyl (AE), diethylaminoethyl (DEAE), sulpho (S), sulphomethyl (SM), sulphopropyl (SP), carboxy (C), and carboxymethyl (CM). Successful packing of the column is an important aspect of ion chromatography. Stability and efficiency of a final column depends on packing methods, solvent used, and factors that affect mechanical properties of the column.
Sources: en.wikipedia.org
=== Differential diagnosis === To diagnose PMOS, other conditions must first be ruled out. These include thyroid disease (assessed via thyroid stimulating hormone), hyperprolactinemia (assessed via prolactin), and non-classic congenital adrenal hyperplasia (tested via 17-hydroxy progesterone). For those without any periods whatsoever or more severe signs or symptoms, further tests are recommended to exclude hypogonadotropic hypogonadism, any androgen-producing tumors or Cushing's disease. Overt virilisation (development of male sex characteristics) is not characteristic of PMOS and indicates that another underlying condition may be responsible.
=== Hormonal interactions === Progesterone has a number of physiological effects that are amplified in the presence of estrogens. Estrogens through estrogen receptors (ERs) induce or upregulate the expression of the PR. One example of this is in breast tissue, where estrogens allow progesterone to mediate lobuloalveolar development. Elevated levels of progesterone potently reduce the sodium-retaining activity of aldosterone, resulting in natriuresis and a reduction in extracellular fluid volume. Progesterone withdrawal, on the other hand, is associated with a temporary increase in sodium retention (reduced natriuresis, with an increase in extracellular fluid volume) due to the compensatory increase in aldosterone production, which combats the blockade of the mineralocorticoid receptor by the previously elevated level of progesterone.
== Side effects == Side effects of oral minoxidil may include salt retention, water retention and edema, rapid heartbeat, dizziness, lightheadedness, headaches, and hypertrichosis (excessive hair growth). Topically applied minoxidil is generally well-tolerated, but common side effects include itching of the eyes, general itching, irritation at the treated area, and unwanted hair growth elsewhere on the body. Alcohol and propylene glycol present in some topical preparations may dry the scalp, resulting in dandruff and contact dermatitis. Sublingual minoxidil may have reduced side effects with retained effectiveness compared to oral minoxidil. This is due to less minoxidil sulfate being formed during first-pass metabolism and due to local activation of minoxidil into minoxidil sulfate within hair follicles. In a preliminary clinical trial, no adverse effects or changes in blood pressure occurred with low-dose sublingual minoxidil. Oral minoxidil has been implicated in causing pericarditis, pericardial effusion, and pleural effusion. Cardiac tamponade secondary to pericardial effusion, which can be life-threatening, is also known to occur. Pericardial effusion has been found to occur in about 3% of people at hypertension doses. This is usually associated with impaired renal function, connective tissue disease, uremic syndrome, congestive heart failure, or marked fluid retention, though cases without these potential risk factors have also been reported.
Sources: en.wikipedia.org
Major regulatory agencies have not approved it for any indication. Some countries permit it only under prescription frameworks, while others classify it as a controlled substance.
Much of the evidence comes from case reports and accounts of unregulated use rather than controlled trials. Differences in product purity and dosing add further variability.
Laboratory work focuses on receptor binding and cellular signalling. Observational reports document outcomes after use, and analytical chemists examine samples to assess content and purity.
No regulatory agency has authorised melanotan-2 as a medicine for any indication. It circulates mainly as a research chemical or through unregulated channels. As a result, identity, purity and content are not independently guaranteed.